Matthew C. Hill - 19 Oct 2021 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role: Chief Financial Officer
Signature: /s/ Matthew C. Hill
Issuer symbol: PDSB
Transactions as of: 19 Oct 2021
Net transactions value: $0
Form type: 4
Filing time: 20 Oct 2021, 16:31:00 UTC
Previous filing: 20 Oct 2021
Next filing: 14 Dec 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PDSB	Stock Option (Right to Buy)	Award	$0	+202,800		$0.000000	202,800	19 Oct 2021	Common Stock	202,800	$12.03	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on October 19, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Content

The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on October 19, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.